EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Increased anti‐apoptotic ( B cl‐2+) and decreased proliferative ( Ki ‐67+) cell fractions during the different maturation stages of bone marrow cell populations in MDS and AML : The potential diagnostic impact of the Bcl ‐2: Ki ‐67 ratio

Stefan G C Mestrum iD, Tom Schoenmakers iD, Sixuan J Wang, Norbert C J de Wit, Bert T Boonen, Wouter L W van Hemert, Ruben Deneer iD, Anton H N Hopman iD, Frans C S Ramaekers, Math P G Leers iD

Cytometry Part B: Clinical Cytometry · 2025

DOI: 10.1002/cyto.b.22231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cytometry Part B: Clinical Cytometry, 2025. Verfasst von Stefan G C Mestrum und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics & Cell Biology, GROW-Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The N…. Hauptthemen laut MEDLINE: Ki-67 Antigen, Proto-Oncogene Proteins c-bcl-2, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The relationship between apoptosis inhibition and cell proliferation was studied during the maturation stages of erythropoiesis, granulopoiesis, and monopoiesis in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The anti‐apoptotic and proliferative cell fractions were determined in bone marrow aspirates derived from 25 MDS patients and 25 AML patients and compared to 50 nonmalignant cases, using antibodies to Bcl‐2 and Ki‐67, respectively. These were applied along with ten‐color flow cytometry of maturation markers for the three hematopoietic cell lineages. Next, the Bcl‐2:Ki‐67 ratio was determined as the ratio between the Bcl‐2+ and Ki‐67+ cell fractions of the specific hematopoietic cell lineages, both in total and during the different stages of maturation. Bone marrow samples from MDS and AML patients showed a significant increase in the anti‐apoptotic cell fraction and a reduced proliferative cell compartment compared to non‐malignant cases. Overall, the anti‐apoptotic cell fraction was particularly increased in the more mature stages, while the proliferative cell fractions were decreased more frequently in the immature stages. These changes varied among different hematopoietic cell lineages. The erythropoietic maturation process showed the most significant differences in both Ki‐67+ and Bcl‐2+ cell fractions when comparing MDS and AML to non‐malignant cases. This difference was restricted to that of the Bcl‐2+ cell fractions in the granulopoiesis and that of the Ki‐67+ cell fraction of the monopoiesis. All three hematopoietic cell lineages encompass a small fraction of cells (up to 10%) that concurrently exhibit anti‐apoptotic and proliferative marker expression. Although MDS and AML patients displayed considerable variability in their anti‐apoptotic and proliferation index, the Bcl‐2:Ki‐67 ratio resulted in a clear separation between the malignant and non‐malignant cases. Incorporating this combination of the Bcl‐2 and Ki‐67 markers into the study of MDS and AML and in future diagnostic workups may provide important insights into the biological behavior of these blood‐borne neoplasms and facilitate personalized therapy decisions for patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ki-67 AntigenProto-Oncogene Proteins c-bcl-2Myelodysplastic SyndromesLeukemia, Myeloid, AcuteBone Marrow CellsHumansCell ProliferationAgedMaleFemaleMiddle AgedApoptosisFlow CytometryAged, 80 and overAdult

Stichwörter der Autor:innen

AMLBcl‐2Ki‐67MDSMultiparameter flow cytometryanti‐apoptosishematopoietic cell lineagesmaturationproliferation

Substanzen

Ki-67 AntigenProto-Oncogene Proteins c-bcl-2

Autor:innen und Institutionen

  • Department of Genetics & Cell Biology, GROW-Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Department of Clinical Chemistry & Hematology, Zuyderland Medical Center, Sittard-Geleen, The Netherlands.
  • Central Diagnostic Laboratory (CDL), Maastricht University Medical Center, Maastricht, The Netherlands.
  • Department of Orthopedic Surgery, Zuyderland Medical Center, Heerlen, The Netherlands.
  • Nordic-MUbio, Part of Vector Laboratories Inc., The Netherlands.
  • Department of Environmental Sciences, Faculty of Science, Open Universiteit, Heerlen, The Netherlands.

ORCID-Profile: Stefan G C Mestrum, Tom Schoenmakers, Ruben Deneer, Anton H N Hopman, Math P G Leers

Zitieren

APA

Mestrum, S. G. C., Schoenmakers, T., Wang, S. J., de Wit, N. C. J., Boonen, B. T., van Hemert, W. L. W., Deneer, R., Hopman, A. H. N., Ramaekers, F. C. S., & Leers, M. P. G. (2025). Increased anti‐apoptotic ( B cl‐2+) and decreased proliferative ( Ki ‐67+) cell fractions during the different maturation stages of bone marrow cell populations in MDS and AML : The potential diagnostic impact of the Bcl ‐2: Ki ‐67 ratio. Cytometry Part B: Clinical Cytometry. https://doi.org/10.1002/cyto.b.22231

Vancouver

Mestrum SGC, Schoenmakers T, Wang SJ, de Wit NCJ, Boonen BT, van Hemert WLW, et al. Increased anti‐apoptotic ( B cl‐2+) and decreased proliferative ( Ki ‐67+) cell fractions during the different maturation stages of bone marrow cell populations in MDS and AML : The potential diagnostic impact of the Bcl ‐2: Ki ‐67 ratio. Cytometry Part B: Clinical Cytometry. 2025. doi:10.1002/cyto.b.22231

BibTeX
@article{Mestrum2025,
  author = {Mestrum, Stefan G C and Schoenmakers, Tom and Wang, Sixuan J and de Wit, Norbert C J and Boonen, Bert T and van Hemert, Wouter L W and Deneer, Ruben and Hopman, Anton H N and Ramaekers, Frans C S and Leers, Math P G},
  title = {Increased anti‐apoptotic ( B cl‐2+) and decreased proliferative ( Ki ‐67+) cell fractions during the different maturation stages of bone marrow cell populations in MDS and AML : The potential diagnostic impact of the Bcl ‐2: Ki ‐67 ratio},
  journal = {Cytometry Part B: Clinical Cytometry},
  year = {2025},
  doi = {10.1002/cyto.b.22231}
}
Kostenlos starten →